Zolpidem

N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide

Ambien, Intermezzo, Edluar, Stilnoct, Stilnox

Psychoactive Class

Sedative Depressant Atypical Hallucinogen

Chemical Class

Z-drug (nonbenzodiazepine hypnotic)Imidazopyridine

Zolpidem is a nonbenzodiazepine hypnotic of the imidazopyridine class, first approved by the FDA in 1992 for the treatment of insomnia.¹² It acts at the GABA-BZ receptor complex, sharing pharmacological properties with benzodiazepines while producing comparatively less anxiolysis, muscle relaxation, and anticonvulsant activity.¹ At higher doses, zolpidem can produce realistic hallucinations resembling those of deliriants, significant amnesia, and marked disinhibition.¹

Dosage & Duration

Dosage

Threshold~2.5 mg

Light2.5-5 mg

Moderate5-10 mg

Strong10-20 mg

Heavy20+ mg

Bioavailability

~70%

Associated with complex sleep behaviors, in which activities are performed during sleep and followed by amnesia. Sedation and impairment may persist for up to 7 hours after hypnotic-range doses.

Duration

Onset15-45 minutes

After Effects1-24 hours

Total5-10 hours

Half-life

2-3 hours

Subjective Effects

At standard medical doses, the experience consists of little beyond sedation, with drowsiness, decreased alertness, and dizziness dominating and negative effects remaining mild. At common to strong doses, the character of the experience can shift considerably, with reports of euphoria, open- and closed-eye visuals, and realistic hallucinations comparable to those of deliriants. Anterograde amnesia becomes very likely at higher doses, and inhibitions can be lowered to the point that users act in ways they would not while sober.

Physical

The body experience centers on heavy somnolence and sedation alongside dizziness and reduced psychomotor performance and coordination. Impairment can persist into the following day, particularly at higher doses or with extended-release formulations.

Sedation

Central nervous system depression is the core physical effect and the basis of the drug's hypnotic use.

Dizziness

Cognitive

The headspace is dominated by sedation and impaired recall; memory of events during peak effects is frequently partial or absent at doses above 10 mg. Euphoria and anxiety relief occur only inconsistently, while lowered inhibitions and delusional thinking are reported at higher doses.

Delusion

Emotional

Positive emotional effects are inconsistent and dose-dependent.

Libidinal

Increased libido Decreased libido

Suppressions

Visual

Closed- and open-eye visuals are rarely noted at 10 mg and appear more often, though still unreliably, at common to strong doses.

Hallucinatory States

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Zolpidem acts as a positive allosteric modulator at GABAA receptors, binding at the benzodiazepine site to enhance GABAergic inhibition in the central nervous system.³ It exhibits pronounced selectivity for GABAA receptors containing the α1 subunit, with approximately 10-fold lower affinity for α2- and α3-containing receptors and no appreciable affinity for those containing the α5 subunit.³ This subunit selectivity confers strong hypnotic properties with comparatively weak anxiolytic, myorelaxant, and anticonvulsant activity.³

Pharmacokinetics

Zolpidem is rapidly absorbed from the gastrointestinal tract with an absolute oral bioavailability of approximately 70%,⁴ reaching peak plasma concentrations within roughly 1.6 to 2 hours.³ The elimination half-life in healthy adults is approximately 2 to 3 hours.³ Hepatic metabolism is the primary route of elimination, predominantly via CYP3A4 (approximately 61%), with contributions from CYP2C9 (22%), CYP1A2 (14%), and minor involvement of CYP2D6 and CYP2C19 (each less than 3%).⁵ Less than 1% of the drug is excreted unchanged in urine, and all three principal metabolites are pharmacologically inactive.³

Interactions

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

1,2-BenzodiazepineAbametapirAbataceptAbirateroneAbrocitinib

TripSit

Tolerance

Full Tolerance

Zolpidem demonstrates a favorable tolerability profile with low risk of tolerance development when used according to prescribing guidelines. Clinical studies have shown maintained efficacy in decreasing sleep latency for up to 35 days of continuous use.

Cross Tolerance

Benzodiazepines, Other GABA-A receptor positive allosteric modulators, Z-drugs (nonbenzodiazepine hypnotics)

Harm Potential

Addiction & Dependence

Psychological

Moderate

Zolpidem misuse has been associated with dependence and addiction, often driven by its euphoric effects.⁶ A 2014 review found evidence of drug-seeking behavior, with zolpidem prescriptions making up 20% of falsified or forged prescriptions. Recreational use is more prevalent in those with a history of drug dependence, though addiction can develop in individuals without such history.

Physical

Moderate

Physical dependence develops with prolonged use, producing withdrawal symptoms resembling benzodiazepine withdrawal.¹ Abrupt discontinuation may cause tremors, delirium, irritability, and in severe cases, seizures.¹ Reported cases of high-dose dependence document daily doses up to 6,000 mg, with tapering or benzodiazepine substitution typically required for discontinuation.⁷

Toxicity

Central Nervous System

CNS depressant effects including somnolence, respiratory depression, and impaired consciousness occur during intoxication; organ toxicity is rare even at high doses, though severe CNS effects can occur with overdose or extreme use.¹

Cognitive/Memory

Anterograde amnesia may occur, particularly at doses above 10 mg; a marked reduction in next-morning recall of information relayed during peak drug effect has been observed in controlled studies.¹

Carcinogenicity

Possible

Two-year animal studies showed no evidence of carcinogenicity in mice; renal tumors observed in rats were attributed to spontaneous occurrence.¹ Zolpidem showed no mutagenic activity in multiple genotoxicity assays.¹ However, a 2017 meta-analysis of epidemiological studies found zolpidem use associated with a 34% increased cancer risk, though results were tentative due to confounding factors including smoking and alcohol use.⁹

Evidence Basis

Human EpidemiologicalLimited

Animal Models

Negative

(rat, mouse)

In Vitro

non-genotoxic

Ames test, mouse lymphoma cells, chromosomal aberration assay, micronucleus test

MechanisticNone

Psychosis Risk

Hallucinations through multiple senses and delusions are reported, particularly at higher doses.¹⁰ Complex sleep behaviors with amnesia are well-documented.¹ Delirium may occur during withdrawal from chronic use.¹ Visual hallucinations have been noted more frequently when zolpidem is combined with antidepressants.¹⁰

Seizure Risk

Seizures are primarily a withdrawal risk rather than an acute effect.¹ Abrupt discontinuation after prolonged use or high doses may cause seizures, particularly in chronic users who have developed physical dependence.¹¹¹ Gradual dose reduction is recommended to minimize this risk.

History & Culture

Development and Approval

Zolpidem entered clinical use in Europe in 1988 through the pharmaceutical company Synthelabo. Following its European introduction, Synthelabo collaborated with Searle to pursue regulatory approval in the United States. The FDA granted approval in 1992, and the drug was marketed under the brand…

Legality

By Country

United StatesSchedule IV controlled substance

Zolpidem is Schedule IV under the Controlled Substances Act²¹ and was approved for U.S. medical use in 1992.²²

References

Source Pages

Citations

Suggest an edit